Sylvester Comprehensive Cancer Center, University of Miami | Strategic Alliance Partners

July 28, 2022

Cancer experts at the Sylvester Comprehensive Cancer Center: Annual Oncology Update shared important progress across a wide range of cancers — prostate cancer, breast cancer, colon cancer, and more — that was presented at the American Society of Clinical Oncology 2022 Annual Meeting, the largest gathering of cancer clinicians and scientists in the United States.

June 27, 2022

A team of researchers with Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine has identified a new cellular oxygen-sensing pathway – a discovery that could potentially lead to new approaches for treating cancer and other diseases.

June 23, 2022

Sylvester Comprehensive Cancer Center is making another bold move to accelerate cancer research, celebrating the groundbreaking for a 244,000-square-foot, state-of-the-art Sylvester Comprehensive Cancer Center - Transformational Cancer Research Building.

June 17, 2022

Research underscores the need to subdivide Hispanics and other racial and ethnic groups to fully understand actual disparities.

May 23, 2022

Dr Taylor discusses the significance of BTK inhibition in chronic lymphocytic leukemia, describes the key objectives of, and methods used, for the genomic analyses performed by his team, underscores the clinical significance of the data yielded from this research, and outlines where future efforts will focus.

May 23, 2022

A new study by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine has found that Black women with metastatic breast cancer were less likely to have tumors with treatable genetic variations than white and Asian women.

May 17, 2022

New research illuminates the mechanisms that make B-cell lymphomas resistant to important immunotherapy

May 05, 2022

The Pillai lab will explore off-the-shelf, innate natural killer T cell immunotherapies that can be targeted against challenging tumors.

April 29, 2022

Renowned robotic urologic oncology surgeon Dipen J. Parekh, MD, was the first in the nation to test a new preoperative surgical rehearsal technology recently approved by the FDA for all genitourinary conditions.

April 27, 2022

Justin W. Taylor, MD, discusses findings from a genomic analysis on BTK inhibitors in chronic lymphocytic leukemia.

April 11, 2022

Researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have joined forces with the University of Miami College of Engineering for a collaborative initiative to develop and deploy innovative technologies for early detection, diagnosis, and treatment of cancer.

April 07, 2022

Justin W. Taylor, MD, discusses the significance of BTK inhibition in the treatment of patients with CLL, the genomic analyses conducted in those enrolled to BRUIN who received pirtobrutinib, and the significance of the data yielded from this research.

March 21, 2022

Dorothy Graves, PhD, said she admired Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine years prior to being appointed Sylvester’s assistant vice president and associate director for administration in early 2022.

March 02, 2022

The Bristol Myers Squibb Foundation and National Medical Fellowships have selected Sylvester Comprehensive Cancer Center researcher Kristin E. Rojas, MD, FACS, for its inaugural Diversity in Clinical Trials Career Development Program.

February 11, 2022

A team led by Lluis Morey, PhD, has received a five-year, $1.7 million grant from the National Institute of General Medical Sciences to investigate treatment resistance in estrogen receptor positive breast cancer.

December 13, 2021

Selinexor combined with venetoclax demonstrated efficacy and tolerability in heavily pretreated relapsed/refractory multiple myeloma cell lines with t(11;14), according to small study results that were presented during the 2021 ASH Annual Meeting.

November 24, 2021

Sylvester Comprehensive Cancer Center will provide a leading role in the collaborative effort to eliminate the preventable disease that kills thousands of women around the world.

November 18, 2021

Gina Z. D’Amato, MD, discusses optimizing treatment for patients with desmoid tumors.

September 16, 2021

Estelamari Rodriguez, MD, MPH, discusses the role of immunotherapy in extensive-stage small cell lung cancer.

September 03, 2021

Pirtobrutinib elicited encouraging responses across all dose levels in patients with mantle cell lymphoma and other non-Hodgkin lymphoma who previously received all classes of available therapy, with benefit observed independent of prior therapy received, according to data from the phase 1/2 BRUIN study.